Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Finafloxacin

Drug class: Quinolone Antimicrobial

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Finafloxacin used for?
The FDA-approved label (Xtoro, Fonseca Biosciences, LLC, March 24, 2026) says: “XTORO® is indicated for the treatment of acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients age 1 year and older. XTORO® is a quinolone antimicrobial indicated for the treatment of acute otitis externa (AOE) caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Finafloxacin have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Finafloxacin?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Finafloxacin been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Finafloxacin?
1 company lists prescription products of Finafloxacin in the FDA NDC Directory, including Fonseca Biosciences, LLC.

What Finafloxacin is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

XTORO® is indicated for the treatment of acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients age 1 year and older. XTORO® is a quinolone antimicrobial indicated for the treatment of acute otitis externa (AOE) caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus.

— FDA label: Xtoro, Fonseca Biosciences, LLC, effective March 24, 2026. Read the full label on DailyMed →

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Forms and how it is given

Dosage formsSuspension
RouteAuricular (otic)
Prescription products1 in the FDA NDC Directory
Brand namesXtoro

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA206307
XTORO
Fonseca BiosciencesDecember 17, 2014 3, latest March 18, 2026
2026: Labeling · 2026: Labeling · 2015: Manufacturing (CMC)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)1598645, 1598650
SPL set ID of the quoted label5c628272-019e-4511-8d5c-dcf56023da25
FDA labels (SPL)1
FDA applicationsNDA206307
Active ingredients (FDA)FINAFLOXACIN

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Xtoro, Fonseca Biosciences, LLC, effective March 24, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers